Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06216392
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-22
First Post:
2024-01-11
Brief Title:
Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis
Sponsor:
Genrix Shanghai Biopharmaceutical Co Ltd
Organization:
Genrix Shanghai Biopharmaceutical Co Ltd
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Multi-Center Phase 3 Trial Evaluating the Efficacy Safety and Immunogenicity of GR1802 Injection in Patients With Moderate to Severe Atopic Dermatitis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center randomized double blind placebo-controlled study to evaluate the efficacy safety PK PD and immumogenicity of GR1802 injection in comparison to placebo in patients with atopic dermatitis Patients will receive GR1802 injection or Placebo every 2 Weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None